CERS2 and urinary bladder cancer: Furthermore, Shi et al. (2024) showed that LASS2 enhances chemosensitivity to cisplatin by inhibiting PP2A-mediated β-catenin dephosphorylation in stem-like bladder cancer cells, thereby reducing the transcription of genes associated with drug resistance (17).